A real-world experience of palbociclib-induced adverse events in women with HR-positive/Her2-negative metastatic breast cancer.

Treatment Patterns and Clinical Outcomes Of palbociclib-Based Therapy Received in US Community Oncology Practices

“…The present study contributes to a growing body of real-world evidence of treatment patterns and clinical effectiveness of palbociclib in real-world settings [9][10][11][12][13][14][15][16][17][18]. The objective of this study was to describe patient demographics, clinical characteristics, real-world treatment patterns and effectiveness among women receiving P+AI as initial endocrine-based therapy or P+F after failure of prior endocrine therapy for the treatment of HR+/HER2-aBC/mBC.…”